Evidence map›Paper›PMID 32647483›Full record

ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2020

Experimental and theoretical study on structure-tautomerism among edaravone, isoxazolone, and their heterocycles derivatives as antioxidants.

Auriekson N Queiroz, Camila C Martins, Kelton L B Santos, Ederson S Carvalho, Alex O Owiti, Karen R M Oliveira, Anderson M Herculano, Albérico B F da Silva, Rosivaldo S Borges

Open access · greenAbstract read
In one paragraph

Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Affinity of Antifungal Isoxazolo[3,4-Molecules (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Auriekson N QueirozPharmaceutical Chemistry Laboratory, College of Pharmacy, Health Science Institute, Federal University of Pará, 66075-110 Belém, PA, Brazil.
Camila C MartinsPharmaceutical Chemistry Laboratory, College of Pharmacy, Health Science Institute, Federal University of Pará, 66075-110 Belém, PA, Brazil.
Kelton L B SantosPharmaceutical Chemistry Laboratory, College of Pharmacy, Health Science Institute, Federal University of Pará, 66075-110 Belém, PA, Brazil.
Ederson S CarvalhoPharmaceutical Chemistry Laboratory, College of Pharmacy, Health Science Institute, Federal University of Pará, 66075-110 Belém, PA, Brazil.
Alex O OwitiCalifornia University of Science and Medicine, San Bernardino, CA, United States.
Karen R M OliveiraPrograma de Pós-Graduação em Neurociências e Biologia Celular, Biological Sciences Institute, Federal University of Pará, 66075-110 Belém, PA, Brazil.
Anderson M HerculanoPrograma de Pós-Graduação em Neurociências e Biologia Celular, Biological Sciences Institute, Federal University of Pará, 66075-110 Belém, PA, Brazil.
Albérico B F da SilvaInstituto de Química de São Carlos, Universidade de São Paulo, Avenida Trabalhador São-carlense, 400, São Carlos, SP, Brazil.
Rosivaldo S BorgesPharmaceutical Chemistry Laboratory, College of Pharmacy, Health Science Institute, Federal University of Pará, 66075-110 Belém, PA, Brazil.
Universidade Federal do Pará · BRCalifornia State University, San Bernardino · USUniversidade de São Paulo · BRUniversidade Federal do Amapá · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Edaravone is a heterocyclic pyrazolone compound. It has pronounced effect against free radicals, however renal and hepatic disorders have been reported. Isoxazolones are considered bioisosteric analogues of pyrazolones and may have comparable properties. Thus, we investigated the structural and electronic influences for edaravone, isoxazolone, and their tautomers on antioxidant process. Structure and tautomerism study among edaravone, isoxazolone and their heterocycles derivatives were related to antioxidant mechanisms by using the hybrid DFT method B3LYP with the basis sets 6-31++G(2d,2p). The C-H tautomer was the most stable and energetically favored among them. Intramolecular N-H-N hydrogen bonds and polar medium were responsible for the low energy differences among all possible tautomers. N-H tautomers in both systems proved to be better antioxidant by SET (single electron transfer), while O-H tautomers were better antioxidant on HAT (homolytic hydrogen atom transfer) mechanism. Theoretical calculation showed that edaravone is more potent than phenylisoxazolone, however, both has similar antioxidant scavenging on experimental DPPH. The carbonyliminic system played a very important role in the antioxidant activity for both studied classes.

Indexed as

AntioxidantDFTDPPHEdaravoneHeterocyclesIsoxazoloneTautomerism

Identifiers

PMID32647483
PMCPMC7335820
OpenAlexW3035259512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.